This study is a multi-center observational study.The start time for data collection is May 1, 2024. Patients' baseline and treatment data will be collected under informed concent. The purpose of this case registry study was to evaluate the safety and efficacy of irinotecan hydrochloride liposome injection II based therapy in Chinese patients with pancreatic cancer in the real world by collecting, understanding, and analyzing the etiology, clinical features, treatment pattern, treatment outcomes, and pharmacoeconomics changes in pancreatic cancer patients receiving this regimen.
Study Type
OBSERVATIONAL
Enrollment
3,000
Irinotecan liposome II combination therapy regimen
Anhui Provincial Cancer Hospital
Hefei, Anhui, China
RECRUITINGPeking Union Medical College Hospital
Beijing, Beijing Municipality, China
RECRUITINGThe First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, China
RECRUITINGThe First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
RECRUITINGPeking Unicersity First Hospital
Beijing, China
RECRUITINGHenan Provincial People's Hospital
Henan, China
RECRUITINGNingbo Medical Center Lihuili Hospital
Ningbo, China
RECRUITINGFudan University Shanghai Cancer Center
Shanghai, China
RECRUITINGRenji，Hospital
Shanghai, China
RECRUITINGWuhan Union Hospital of China
Wuhan, China
RECRUITINGrwTEAE
real word treatment emergent adverse event
Time frame: 3 years
OS
real word overall survival
Time frame: 3 years
PFS
real word progression free survival
Time frame: 3 years
ORR
real word objective response rate
Time frame: 3 years
TTP
real word time to progression
Time frame: 3 years
DCR
real word disease control rate
Time frame: 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.